Diabetic retinopathy

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Receptor fusion protein 1 substance
Phase III: 1 Phase I (Other): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Alvotech Swiss AG Commercial
    AFLIBERCEPT
    2023-505225-13-00 1 country 2024 n=23
    Ended

Phase I (Other)

1 trial
  • Breye Therapeutics ApS Commercial
    IMP not specified
    2024-515078-28-00 1 country 2025 n=56
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Breye Therapeutics ApS Commercial 1 Phase I (Other) 0
Alvotech Swiss AG Commercial 1 Phase III 0
New trials by year
2024
1
2025
1
← All indication landscapes